Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
7 citations
,
May 2022 in “International Journal of Environmental Research and Public Health” Isotretinoin therapy for acne can cause many reversible side effects, mainly mild skin conditions, and patient understanding of these effects can improve treatment adherence.
7 citations
,
August 2010 in “Medicinal Chemistry Research” Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
Dutasteride is more effective and better tolerated than finasteride for hair loss treatment.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
52 citations
,
February 2003 in “Archives of dermatology” 9-cis-retinoic acid showed some effectiveness in treating AIDS-related Kaposi sarcoma but had significant side effects at higher doses.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
January 2005 in “Chinese New Drugs Journal” Locally made finasteride tablets work the same as imported ones.
1 citations
,
November 2022 in “INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)” Vitamin D helps reduce depression in people with autoimmune thyroiditis and hypothyroidism.
October 2015 in “Prostate Cancer” Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
October 2023 in “Journal of the American Academy of Dermatology” Clascoterone cream could be used for other skin conditions affected by hormones.
17 citations
,
January 2016 in “Advances in Dermatology and Allergology” Isotretinoin may reduce inflammation by increasing adiponectin and leptin levels.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
August 2006 in “JNCI Journal of the National Cancer Institute” January 2025 in “Thieme Medical and Scientific Publishers Private Limited eBooks” 5 citations
,
June 2012 in “PubMed” Valproic acid can cause a skin condition called leukocytoclastic vasculitis, which usually gets better after stopping the drug.
August 2025 in “Journal of the American Academy of Dermatology”
2 citations
,
July 2019 in “PLOS ONE” Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
January 2026 in “Neurochemistry International” 24-Hydroxycholesterol reduces DHT formation in brain cancer cells, linking cholesterol and hormone metabolism.
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
September 2012 in “PharmacoEconomics & Outcomes News” Finasteride doesn't harm quality of life.
January 2017 in “Rasayan journal of Chemistry” Researchers created a new, efficient way to make Dutasteride, a hair loss and prostate drug, with high purity using a benzoyl group.
3 citations
,
November 2018 in “The Journal of Clinical Psychiatry” Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
10 citations
,
December 2014 in “Journal of Pharmaceutical and Biomedical Analysis” Finasteride's polymorphic form affects capsule quality and drug effect, requiring strict control.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.